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The hypothesis that tumor growth is an-
giogenesis-dependent (Folkman, 1971)
and its subsequent confirmation by
genetic methods (reviewed in Folkman,
2001a; Lyden et al., 2001) provided
strong incentive for scientists to try to tar-
get peptides specifically to the vascular
bed of tumors. Pasqualini and Ruoslahti
achieved the first step toward this goal in
1997 when they reported a novel in 
vivo phage display that distinguished
between active proliferating microvascu-
lar endothelial cells in a tumor and quies-
cent nonproliferating endothelial cells
elsewhere in the vasculature (Pasqualini
et al., 1997).This methodology permitted
angiogenesis-related targeting of tumor
blood vessels. Two years later they
demonstrated that a small peptide could
be specifically targeted to tumor vascula-
ture. The peptide inhibited two metallo-
proteinases, resulting in inhibition angio-
genesis, tumor growth, and invasion
(Koivunen et al., 1999; Folkman, 1999).
Now, in a landmark paper, Arap and
Pasqualini and their colleagues report in
vivo screening of a peptide library in a
patient for the first time (Arap et al.,
2002). Circulating peptides
containing 47,160 motifs local-
ized to the vasculature of differ-
ent organs in a nonrandom dis-
tribution. Furthermore, certain
circulating peptides bound
specifically to known receptors
on the vascular endothelium of
the organ from which the pep-
tide was recovered, but not to
endothelium from other organs.
For example, a prostate hom-
ing phage displaying a peptide
mimic for interleukin-11 specifi-
cally bound to the endothelium
and epithelium of normal
prostate, but not to other
organs such as skin. Some of
the many potential clinical
applications of this elegant
technology were reviewed pre-
viously (Folkman, 1999). In
their current report (Arap et al.,
2002), the authors point out
that it ultimately may become
possible to determine molecu-
lar profiles of blood vessels in
different organs and in specific condi-
tions.
If such a molecular map of the human
vasculature is eventually achieved and
the results are taken together with the
recently identified genes which encode
endothelial markers overexpressed dur-
ing tumor angiogenesis (St. Croix et al.,
2000), a novel pharmacologic approach
to angiogenesis-dependent diseases can
be envisioned. Currently, antiangiogenic
proteins are delivered into the circulation
and achieve their high therapeutic index
by selective inhibition of proliferating and
migrating endothelial cells in an angio-
genic focus, without having a similar
effect on quiescent endothelium in the
remaining vasculature. If these direct
angiogenesis inhibitors, which include
thrombospondin, angiostatin, endostatin
and tumstatin (Maeshima et al., 2002),
among others, could be targeted to the
angiogenic focus in a tumor, in an athero-
sclerotic plaque, or in the retina or
choroid of the eye, potency could be
potentially enhanced.
In antiangiogenic therapy of cancer,
such increased potency may be useful in
the case of tumor cells deficient in p53. It
has been suggested that because these
tumor cells have a diminished rate of
apoptosis under hypoxic conditions, that
they might be less responsive to antian-
giogenic therapy (Yu et al., 2002). For
those angiogenesis inhibitors which
have shown virtually no toxicity or side-
effects in animals or humans (e.g.,
angiostatin, endostatin), increasing the
dose or combining two or more inhibitors
should obviate the problem of p53−/−
tumor cells. Viable tumor cells form
microcylinders around each capillary
blood vessel that has been recruited to
the tumor (Figure 1) (Folkman, 2001b).
With increasing distance from the near-
est blood vessel, tumor cells live under
increasing hypoxia. However, beyond a
given oxygen diffusion limit (which may
be in the range of 110 µm for tumor cells
which are p53+/+ but greater, i.e., in the
range of 150 µm, for p53 null tumor
cells), anoxic conditions cause tumor
cells to die. Because one endothelial cell
controls the survival of approximately 50
to 100 tumor cells, a direct angiogenesis
inhibitor of sufficient potency and dose to
cause endothelial apoptosis
would result in tumor cell
death in the vessel neighbor-
hood (Browder et al., 2000).
However, for those angiogen-
esis inhibitors where dose
cannot be increased because
of the limitation of side-effects
(e.g., TNP-470, a fumagillin
analog [Folkman, 2001a]), tar-
geting to the microvascular
endothelium in a tumor bed
may greatly increase the use-
fulness of the inhibitor.
Whether angiogenesis
inhibitors are administered so
that they reach every tissue at
equivalent concentrations, or
whether these agents are tar-
geted specifically to a focus of
tumor angiogenesis, their suc-
cessful clinical application
depends critically on an
understanding of the differ-
ence between direct and indi-
rect angiogenesis inhibitors. A
direct angiogenesis inhibitor
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The first in vivo screening of a peptide library of the human vasculature opens new possibilities for inhibiting angiogene-
sis and tumor growth.
Figure 1. Histological microsection of prostate carcinoma in a rat
Viable tumor cells (light blue) form a microcylinder around each of
two capillary blood vessels (highlighted orange-brown by antibody to
CD31). The oxygen diffusion limit for this tumor is approximately 110
microns. Beyond that distance (interrupted line), most cells are dead
due to anoxia (dark blue small cells). This figure, previously published
in Folkman (2001b) is a personal communication from L. Hutchinson, L.
Hlatky, and P. Hahnfeldt, and is used with permission.
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targets genetically stable endothelial
cells recruited to a tumor (Figure 2). It
inhibits or arrests their ability to prolifer-
ate, to migrate, or to grow new blood ves-
sels. Some direct angiogenesis
inhibitors, such as endostatin, cause
apoptosis of growing endothelial cells
(Dixelius et al., 2000). Direct angiogene-
sis inhibitors act independently of the
cancer cell genome and are not general-
ly subject to the problems of drug resis-
tance, for the same reason that the
genetic stability of bone marrow usually
prevents it from becoming resistant to
chemotherapy. In contrast, an indirect
angiogenesis inhibitor generally inhibits
a tumor cell product or its receptor
(Figure 3). For example, an antibody
against a tumor-generated pro-angio-
genic protein, VEGF (vascular endothe-
lial growth factor), may successfully
inhibit angiogenesis induced by a tumor
releasing only or mainly VEGF (Figure
3). However, if mutant tumor cells devel-
op which produce other pro-angiogenic
proteins, such as bFGF (basic fibroblast
growth factor) or TGFβ-1 (transforming
growth factor β-1) (Figure 3), the tumor
may resume its angiogenic activity and
appear to become resistant to the indi-
rect inhibitor. In women first diagnosed
with breast cancer, approximately 60%
of tumors produce only VEGF. In subse-
quent recurrences or in metastases,
additional angiogenic proteins are found
(Relf et al., 1997). An indirect angiogene-
sis inhibitor which blocks only VEGF
might be effective early after diagnosis,
but might be less effective in treating
later recurrences because these tumors
are producing multiple pro-angiogenic
proteins. On the other hand, some indi-
rect angiogenesis inhibitors may bring
about complete and durable regression
of a tumor that has failed all conventional
chemotherapy or radiotherapy, if the
angiogenic activity in that tumor is medi-
ated by a pro-angiogenic protein which
remains the same throughout treatment.
For example, certain high grade giant
cell tumors and angioblastomas in
humans in which angiogenesis is medi-
ated only or mainly by bFGF have been
eradicated by treatment with interferon-
α, which blocks production of bFGF
(Singh et al., 1995) by tumor cells
(Figure 3) (Marler et al., 2002).
The in vivo screening of peptide
libraries in patients may have numerous
other applications that cannot be per-
ceived at this early stage of its develop-
ment. For example, such screening may
provide clues to predict metastatic pat-
terns, or it may even be used to detect
the targets of circulating endothelial cells
and stem cells, or to direct these cells to
a prespecified target. This novel
approach to detection of addresses in
the vascular system may also be used in
early detection of neurologic diseases
such as Alzheimer’s disease. For cancer
therapy, however, it is not clear if clini-
cians will always be as dependent on
knowing the precise location of a cancer
as they are today, because of increasing
development of molecular diagnosis.
Nevertheless, molecular diagnosis
depends to a large extent on detection of
molecules shed from a tumor or its vas-
cular bed into a body fluid. A molecular
map of the human vasculature may
come to play a pivotal role in the devel-
opment of molecular diagnosis. If molec-
ular diagnosis of cancer from blood,
urine, stool, and other body fluids contin-
ues to develop, and if the toxicity of can-
cer therapy can be significantly reduced,
there may come a time when a patient
Figure 3. Diagram to illustrate increase in different types of pro-angiogenic proteins released by
human breast cancers (T = tumor) with passage of time (arrows) (Relf et al., 1997)
In contrast, certain tumors, such as high grade giant cell tumors and angioblastomas (left),
continue to produce only or mainly bFGF (Marler et al., 2002).
Figure 2. Diagram of indirect versus direct angiogenesis inhibitors
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with a positive molecular marker for can-
cer will be treated until the marker
becomes negative, perhaps without visu-
alization of the tumor or its metastases.
This scenario is beginning to happen in
recurrent ovarian cancer.
Cancer therapy today is anchored to
a taxonomy of a tumor’s site of origin and
its location (Andrew von Eschenbach,
personal communication). One can spec-
ulate that someday, this paradigm may
shift to a therapy heavily based on molec-
ular markers where site of origin may not
be essential (i.e., for antiangiogenic ther-
apy), and where the need to know the
location of a tumor may not be required.
Such a change in medical practice would
recapitulate the history of the treatment
of infection. Before antibiotics, it was criti-
cal to know the location of an infection so
that pus could be drained; after antibi-
otics, the treatment of many infections
could be guided by markers in the blood.
If cancer can someday be treated as a
chronic manageable disease, analogous
to heart disease or diabetes, the report of
Arap and Pasqualini and their colleagues
(Arap et al., 2002), in addition to its
heuristic value, will have made a major
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